


## Artificial Metalloenzymes for Olefin Metathesis Based on the Biotin-(Strept)avidin Technology

Cheikh Lo, Mark R. Ringenberg, David Gnanndt, Yvonne Wilson and Thomas R. Ward\*

### Supporting information


**General:**  $^1\text{H}$ ,  $^{13}\text{C}$  and  $^{19}\text{F}$  spectra were obtained on a Bruker 400 MHz and 500 MHz. Chemical shifts are reported in ppm (parts per million). Signals are quoted as s (singlet), d (doublet), t (triplet), and m (multiplet). Electron Spray Ionization Mass Spectras (ESI-MS) were recorded on a Bruker FTMS 4.7T bioAPEX II. Analysis of the catalytic runs was performed on an Agilent 1100 reverse phase HPLC. All solvents were degassed prior to use. Imidazolium salt **S1**, boc-**1**, and *N*-tosyl diallylamine were synthesized as previously described in the literature.<sup>1, 2-4</sup>




### Synthesis of biot-**1**

Complex boc-**1** (40 mg, 0.053 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (2 mL) and HCl gas was bubbled through the solution for 1 h at room temperature. The gaseous HCl was generated by drop-wise addition of concentrated  $\text{H}_2\text{SO}_4$  to  $\text{NH}_4\text{Cl}$ . The reaction solution was stirred for an additional 2 h at room temperature. The reaction progress was monitored by thin-layer chromatography (TLC) (Hexane/ $\text{AcOEt}$  2:1). After the reaction was complete, the solvent was evaporated at reduced pressure and the resulting green solid was dissolved in DMF (2 mL). Biotin pentafluorophenol (22 mg, 0.053 mmol) and  $\text{Et}_3\text{N}$  (0.2 mL, 1.4 mmol) were added to the solution, and the reaction solution was stirred for 16 h at room temperature. The solvent was removed under reduced pressure and the crude product was purified on sephadex LH 20 eluted with  $\text{CH}_2\text{Cl}_2$  to yield biot-**1** as a green solid (27 mg, 58%). All attempts to separate the diastereomers of biot-**1** were unsuccessful.

$^1\text{H-NMR}$  (500 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$ : 16.36 (s, 1H), 7.49 (m, 1H), 7.03 – 6.97 (m, 4H), 6.90 – 6.77 (m, 3H), 4.85 (m, 1H), 4.52 (m, 1H), 4.43 (m, 1H), 4.36 (m, 1H), 4.18 (m, 1H), 3.82 (m, 1H), 3.57 (m, 1H), 3.33 (m, 1H), 3.06 (m, 1H), 2.89 (m, 1H), 2.59 (m, 1H), 2.42 – 1.97 (m, 20H), 1.68 – 1.54 (m, 4H), 1.42 – 1.32 (m, 2H), 1.21 (m, 6H).  $^{13}\text{C-NMR}$  (125 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$ : 174.7, 152.2, 145.0, 143.1, 138.7, 136.7, 129.9, 129.8, 122.3, 112.9, 75.2, 63.5, 61.6, 59.9, 55.3, 45.7, 40.5, 35.5, 29.6, 26.6, 25.2, 21.2, 20.5, 17.95. ESI-MS for  $\text{C}_{42}\text{H}_{55}\text{Cl}_2\text{N}_5\text{O}_3\text{RuS}$ : 846.28  $[\text{M}-\text{Cl}]^+$ .



The synthesis of **biot-*m*-ABAOH** was carried out as described in the literature.<sup>5</sup>




### Synthesis of **biot-*m*-ABAOcF<sub>5</sub>**

The acid **biot-*m*-ABAOH** (200 mg, 1.37 mmol) and *N,N'*-dicyclohexylcarbodiimide (283 mg, 1.37 mmol) were dissolved in DMF (35 mL). A solution of pentafluorophenol (506 mg, 2.75 mmol) in DMF (10 mL) was added and the reaction solution was stirred for 16 h at room temperature.

The reaction mixture was filtered and the solvent evaporated. The resulting solid was washed with hexane (50 mL x 3) to yield **biot-*m*-ABAOcF<sub>5</sub>** as a white solid (257 mg, 88%) which was used without further purification

$^1\text{H NMR}$  (400 MHz, DMSO)  $\delta$  10.25 (s, 1H), 8.52 (s, 1H), 7.93 (dt,  $J = 18.0, 9.0$  Hz, 1H), 7.82 (d,  $J = 8.0$  Hz, 1H), 7.57 (t,  $J = 8.0$  Hz, 1H), 6.44 (s, 1H), 6.35 (s, 1H), 4.38 – 4.23 (m, 1H), 4.12 (dd,  $J = 8.9, 3.0$  Hz, 1H), 3.18 – 3.04 (m, 1H), 2.90 – 2.68 (m, 1H), 2.56 (d,

$J = 12.4$  Hz, 1H), 2.40 – 2.23 (m, 2H), 1.83 – 1.51 (m, 6H).  $^{13}\text{C}$  NMR (101 MHz, DMSO)  $\delta$  172.63, 164.84, 163.58, 142.05, 141.07, 134.54, 130.85, 128.46, 127.14, 126.30, 122.96, 121.08, 61.90, 60.06, 56.25, 40.72, 37.09, 34.21, 30.25, 28.96, 25.82.  $^{19}\text{F}$  NMR (376 MHz, DMSO) -153.23 (d,  $J = 19.6$  Hz), -157.28 (t,  $J = 23.3$  Hz), -162.01 (dd,  $J = 23.2, 19.7$  Hz). ESI-MS for  $\text{C}_{23}\text{H}_{20}\text{F}_5\text{N}_3\text{NaO}_4\text{S}$ : 552.1.



### Synthesis of biot-*m*-ABA-1

Complex **biot-*m*-ABA-1** was synthesized following the same procedure used for the synthesis of **biot-1**, using **biot-*m*-ABAOC<sub>6</sub>F<sub>5</sub>** (35 mg, 0.066 mmol) and **boc-1** (50 mg, 0.066 mmol). The crude product was purified on sephadex LH 20 using  $\text{CH}_2\text{Cl}_2$  as eluent to yield **biot-*m*-ABA-1** as a green solid. (23 mg, 35%). All attempts to separate the diastereomers of **biot-*m*-ABA-1** were unsuccessful.

$^1\text{H}$ -NMR (500 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$ : 16.38 (s, 1H),  $\delta$  7.89 (s, 1H), 7.71 (s, 1H), 7.49 (m, 1H), 7.38 (m, 1H), 7.25 (m, 1H), 7.06 – 6.94 (m, 4H), 6.90 – 6.77 (m, 3H), 4.84 (m, 1H), 4.73 (m, 1H), 4.60 (m, 1H), 4.34 (m, 1H), 4.19 (m, 1H), 3.93 (m, 1H), 3.75 (m, 1H), 3.57 (m, 1H), 3.04 (m, 1H), 2.80 (m, 1H), 2.55 (m, 1H), 2.38 – 2.01 (m, 20H), 1.70 – 1.52 (m, 4H), 1.41 – 1.33 (m, 2H), 1.19 (m, 6H).  $^{13}\text{C}$ -NMR (125 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$ : 152.3, 151.8, 145.1, 142.8, 138.5, 134.4, 131.1, 130.3, 129.9, 129.5, 122.8, 122.3, 118.2, 113.0, 75.2, 63.6, 61.5, 60.6, 55.6, 42.1, 40.5, 36.5, 29.6, 27.9, 27.6, 25.1, 21.0, 20.7, 17.8. ESI-MS for  $\text{C}_{49}\text{H}_{60}\text{Cl}_2\text{N}_6\text{O}_4\text{RuS}$ : 965.33 [M-Cl] $^+$ .

### General procedure for ring closing methathesis of *N*-tosyl diallylamine.

A 9 mM stock solution of the complex (either **biot-1** or **biot-*m*-ABAB-1**) was prepared by adding DMSO (50  $\mu$ L) to an aliquot of the complex (0.36  $\mu$ mol). A 183 mM stock solution of *N*-tosyl diallylamine (27  $\mu$ L, 91.6  $\mu$ mol in 500  $\mu$ L DMSO) was prepared in a separate vial. In a pyrex tube was added a 0.25 mM stock solution of protein in buffer or water (100  $\mu$ L), followed by the addition of the catalyst's stock solution (10  $\mu$ L) and the mixture was vortexed for one minute. The *N*-tosyl diallylamine (10  $\mu$ L of the stock solution) was added and the reaction flask was placed in an orbital shaker for 16 h at 40°C. Experiments under rigorous exclusion of oxygen were carried in a glove box and gave identical results.

Upon completion of the reaction, a 15 mM solution of phenylethanol (120  $\mu$ L, used an internal standard) was added to the reaction vial, followed by MeOH (800  $\mu$ L). The solution was transferred to an eppendorf tube and centrifuged at 14'000 rpm for 2 minutes. The supernatant (800  $\mu$ L) was transferred in an HPLC vial and water (800  $\mu$ L) was added. The sample was subjected to RP-HPLC to determine the conversion.

Experiments in which the concentration of catalyst, MgCl<sub>2</sub>, and pH were varied were performed in the same manner, taking care to maintain the same DMSO : water ratio.



**HPLC analysis.** Column: XDB-C18, Eclipse by Agilent: 150 x 4.6 mm; 5  $\mu$ m with guard column. Method: V<sub>injected</sub>: 6  $\mu$ l. Eluent (Solvent A H<sub>2</sub>O) , (Solvent B: CH<sub>3</sub>CN) 10% B at 0 min, 10% B at 5 min; 90% B at 15 min; 90 % B at 20 min. Detection at 210 nm.

Retention times: Phenylethanol (internal standard): 10.7 min; *N*-tosyl-3-pyrroline: 13.5 min; *N*-tosyl diallylamine: 15.3 min.


### **Binding constant determination by CD spectroscopy**

In order to determine the affinity of **biot-spacer-1** for (strept)avidin, a substitution titration was carried out using CD-spectroscopy, by following the disappearance of the induced CD-signal of HABA  $\subset$  (strept)avidin (eq. 1-2). Upon addition of aliquots of the biotinylated complex (either **biot-1** or **biot-*m*-ABA-1**) to HABA  $\subset$  (strept)avidin, the induced CD-signal

caused by the supramolecular inclusion complex  $\text{HABA} \subset (\text{strept})\text{avidin}$  decreases, thus allowing to follow the exchange of HABA for either **biot-1** or **biot-*m*-ABA-1**. The resulting CD data were analyzed and fitted using Specfit as described elsewhere.<sup>6</sup> This substitution titration offer the advantage that the curve used for fitting corresponds to the  $K_{\text{exch}}$  (eq. 2). Thanks to this procedure, significantly higher overall binding affinities  $K_{\text{tot}} = K_{\text{a}} \cdot K_{\text{exch}}$  can be fitted reliably.



(Strept)avidin (8  $\mu\text{M}$  initial concentration in Tris-HCl buffer pH = 7, 2.4mL, 19.2 nmol) were charged with a large excess of HABA (9.6 mM stock solution in Tris-HCl buffer pH = 7, 50- and 150 equivalents relative to Avi and Sav tetramer respectively). Aliquots of solutions of **Biot-1** or **Biot-*m*-ABA-1** (0.96 mM in MeOH) were added to  $\text{HABA} \subset \text{avidin}$  in 0.25 equiv. steps (5  $\mu\text{L}$ ) up to 7 equivalents relative to the monomer. The CD spectra (450 – 600nm, band width 1 nm, 30 nm/min, 3 accumulations) were recorded after stirring (5 min at room temperature).




**Figure S1.** Measured (open symbols) and fitted (solid lines) ellipticity profiles at 530 nm for the HABA  $\subset$  (strept)avidin substitution titration by **Biot-*m*-ABA-1** in Sav (pH 7.0, 0.5 M MgCl<sub>2</sub>, red symbols) and **Biot-1** in the presence of Avi (pH 7.0, blue symbols).


### Fluorescence Titration of Avidin with Biot-1

A standard solution of Avidin (0.150  $\mu$ M initial concentration in acetate buffer pH = 4) was treated with **Biot-1** (33 mM, in acetate buffer pH = 4) in  $\sim$ 0.5 equiv. (2  $\mu$ L) steps to tetrameric Avidin. The concentration of free Avidin was determined by fluorescence quenching, in which the excitation monochromator was set at 290 nm using a bandwidth of 4 nm, and the fluorescence was monitored after each addition at 350 nm using a bandwidth of 12 nm.<sup>7</sup>

7



**Figure S2.** Titration of Avidin with **Biot-1** excitation at 290 nm using a bandwidth of 4 nm, emission monitored at 350 nm using a bandwidth of 12 nm.



**Figure S3.**  $^1\text{H-NMR}$  of biot-1 in  $\text{CD}_2\text{Cl}_2$




Figure S4.  $^1\text{H-NMR}$  of biot-*m*-ABA-1 in  $\text{CD}_2\text{Cl}_2$

#### Literature cited

- (1) Jordan, J. P.; Grubbs, R. H. *Angew. Chem. Int. Ed.* **2007**, *46*, 5152.
- (2) Bieniek, M.; Michrowska, A.; Gulajski, L.; Grela, K. *Organometallics* **2007**, *26*, 1096.
- (3) Gessler, S.; Randl, S.; Blechert, S. *Tetrahedron Let.* **2000**, *41*, 9973.
- (4) Miyaki, Y.; Onishi, T.; Ogoshi, S.; Kurosawa, H. *J. Organomet. Chem.* **2000**, *616*, 135.
- (5) Skander, M.; Humbert, N.; Collot, J.; Gradinaru, J.; Klein, G.; Loosli, A.; Sauser, J.; Zocchi, A.; Gilardoni, F.; Ward, T. R. *J. Am. Chem. Soc.* **2004**, *126*, 14411.
- (6) Loosli, A.; Rusbandi, U. E.; Gradinaru, J.; Bernauer, K.; Schlaepfer, C. W.; Meyer, M.; Mazurek, S.; Novic, M.; Ward, T. R. *Inorg. Chem.* **2006**, *45*, 660.
- (7) Lin, H.J.; Kirsch, J.F. *Anal. Biochem.* **1977**, *81*, 442